News Formal

AstraZeneca chief quits CSL board over $50 billion acquisition

  • 📰 smh
  • ⏱ Reading Time:
  • 18 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 80%

Italia Notizia Notizia

Italia Ultime Notizie,Italia Notizie

AstraZeneca chief quits CSL board over $50 billion acquisition | MsEmmaK

AstraZeneca chief executive Pascal Soriot will leave CSL’s board just months after being appointed over fears of a potential future conflict of interest between the two biotechnology giants.

Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player. Mr Soriot was not set to be directly involved in discussions about the AstraZeneca vaccine production and it was planned he would abstain from board issues where there was a potential conflict of interest.

 

Grazie per il tuo commento. Il tuo commento verrà pubblicato dopo essere stato esaminato.

MsEmmaK I cant understand why no one is providing information on the CSL: manufacturing of AZ vaccine in Melbourne

MsEmmaK Are any Liberal involved in insider trading in this company ?

Abbiamo riassunto questa notizia in modo che tu possa leggerla velocemente. Se sei interessato alla notizia puoi leggere il testo completo qui. Leggi di più:

 /  🏆 6. in İT

Italia Ultime Notizie, Italia Notizie

Similar News:Puoi anche leggere notizie simili a questa che abbiamo raccolto da altre fonti di notizie.

AstraZeneca chief quits CSL board over $50 billion acquisitionAstraZenaca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup. Too late insider trading information already used
Fonte: theage - 🏆 8. / 77 Leggi di più »